Valuation: Clarity Pharmaceuticals Ltd

Market Cap 1.04B 738M 639M 599M 546M 1.03B 70.39B 7.06B 2.75B 35.24B 2.77B 2.71B 118B P/E 2026 *
-9.52x
P/E 2027 * -8.75x
Enterprise Value 884M 624M 541M 507M 462M 870M 59.54B 5.97B 2.33B 29.8B 2.34B 2.29B 99.42B EV / Sales 2026 *
-
EV / Sales 2027 * 1,066x
Free-Float
79.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.36%
1 week+3.70%
Current month+18.14%
1 month+16.18%
3 months-1.75%
6 months-7.59%
Current year-17.16%
1 week 2.54
Extreme 2.54
2.96
1 month 2.03
Extreme 2.03
2.96
Current year 1.8
Extreme 1.8
4.26
1 year 1.8
Extreme 1.8
5.87
3 years 0.92
Extreme 0.92
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 2024-10-10
Chief Executive Officer - 2009-12-31
Director of Finance/CFO - 2022-04-03
Director TitleAgeSince
Chairman - 2013-10-31
Director/Board Member - 2010-09-30
Director/Board Member 72 2016-03-28
Date Insider Type Main position Quantity % Market Cap.
11/28/25 Free

Chief Operating Officer

199,909 0.0537%
11/28/25 Free

Chief Operating Officer

287,530 0.0773%
11/28/25 Free

Chairman

744,922 0.2003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%+3.70% - - 742M
Average -0.36%
Weighted average by Cap. -0.36%

Financials

2026 *2027 *
Net sales - 933K 659K 571K 535K 488K 919K 62.89M 6.3M 2.46M 31.48M 2.47M 2.42M 105M
Net income -108M -76.21M -66.06M -61.93M -56.47M -106M -7.27B -729M -285M -3.64B -286M -280M -12.15B -121M -85.37M -74M -69.37M -63.25M -119M -8.15B -817M -319M -4.08B -321M -314M -13.61B
Net Debt -161M -114M -98.53M -92.36M -84.22M -158M -10.85B -1.09B -425M -5.43B -427M -418M -18.12B -49.5M -34.95M -30.29M -28.4M -25.89M -48.72M -3.34B -334M -131M -1.67B -131M -128M -5.57B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
-
Date Price Change Volume
26-08-13 A$2.800 -0.36% 1,340,798
26-08-12 A$2.810 -1.75% 1,513,138
26-08-11 A$2.860 +0.70% 1,823,533
26-08-10 A$2.840 +5.58% 3,976,187
26-08-07 A$2.690 +0.37% 2,280,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.800AUD
Average target price
7.202AUD
Spread / Average Target
+157.23%

Annual profits - Rate of surprise